Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4396504 | 0.74 | NPSR1 (0.30) | — | |
| SCHEMBL19306392 | 0.71 | MEN1 (0.32) | MEN1LMNAKMT2A | |
| SCHEMBL7121422 | 0.70 | — | — | |
| SCHEMBL11135809 | 0.70 | — | — | |
| SCHEMBL11833680 | 0.69 | CYP19A1 (0.34) | MEN1KMT2AALDH1A1 | |
| SCHEMBL7568134 | 0.68 | MEN1 (0.35) | MEN1LMNAKMT2A | |
| SCHEMBL11881419 | 0.67 | MEN1 (0.34) | MEN1LMNAKMT2A | |
| SCHEMBL11287722 | 0.66 | TOP1 (0.46) | MEN1LMNAKMT2AALDH1A1POLB | |
| SCHEMBL11287720 | 0.66 | TOP1 (0.46) | MEN1LMNAKMT2AALDH1A1POLB | |
| SCHEMBL10573499 | 0.65 | MEN1 (0.30) | MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63083040-A | — | — | None | — | — | JP | disclosed |
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | disclosed |
| CN-101494999-A | Method for using organic compound | GIVAUDAN SA (CH) | 2009-07-29 | — | — | CN | disclosed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | disclosed |
| JP-S6383040-A | PRODUCTION OF HYDROXYALKYLCYCLOPENTENONE DERIVATIVE | SUMITOMO CHEM CO LTD | 1988-04-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311403-A1 | Method of Using Organic Compounds | MGLL, GK, LIPC | MEN1 1073/4885LMNA 1235/4885KMT2A 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.